A Single-centre, Randomized, Double-blind (Sponsor Open), Placebo-controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GSK2983559, in Single (in Both Fed and Fasted States) and Repeat Oral Doses in Healthy Participants
Latest Information Update: 03 Jul 2023
At a glance
- Drugs GSK-2983559 (Primary)
- Indications Inflammatory bowel diseases
- Focus Adverse reactions; First in man
- Sponsors GlaxoSmithKline; GSK
- 07 Jan 2020 Status changed from suspended to discontinued.
- 10 Oct 2019 Status changed from recruiting to suspended.
- 26 Jun 2019 Planned number of patients changed from 58 to 62.